Switzerland Archives

News and Trends 1 May 2015

Galderma steps into the Nutraceutical Market

Galderma entered the functional food market thanks to its acquisition of certain assets of Innéov Group. The company, a global leader committed to dermatology and skin health, is fully-owned by Nestlé Skin Health. On April 24th Nestlé Skin Health announced that Galderma, its company focused on medical solutions, has come to an agreement under which it […]

May 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 1 May 2015

Addex Therapeutics: When one of the leading Swiss Biotech startups relives

Biotech startups are risky. They need lot of cash to come across the very regulated clinical path and can fail rapidly when bad results show up. Addex Therapeutics, a Swiss Geneva-based Biotech company, has raised more than €200M throughout its existence and signed deals worth more than €1Bn with Merck and J&J. Yet, on the 31st May 2013, the company almost […]

May 1, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Apr 2015

A new Microfluidic Chip technology raised €1.9Million

Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round was led by Redalpine Venture Partners in Zurich with the participation of private investors from Switzerland and the United Kingdom. Lunaphore’s young team wants to use this cash to develop its first tissue diagnostics platform. The young Swiss medtech company, […]

April 30, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

[Interview] Smartbone, using bioengineering to repair your bones!

Orthobiology is a field of biomedical technology, which develops new devices and products for skeletal regenerative medicine. IBI sa (Industrie Biomediche Insubri sa) is a Swiss-based company excelling in this field. I met Giuseppe Perale, co-founder and President of the company, who not only gave me the big picture on this field, but also on […]

April 22, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 13 Apr 2015

Humabs and MedImmune partnership to develop an Influenza A treatment

Medimmune starts phase I clinical trial to investigate an antibody developed under a collaboration with Humabs BioMed for the treatment of influenza A. The novel antibody developed through Humabs’ Cellclone technology will be investigated a trial being conducted by MedImmune, the global biologics research and development arm of AstraZeneca. The investigational antibody, which has broad influenza-neutralizing […]

April 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

CRISPR Therapeutics opens Boston R&D Office to Win the CRISPR War

CRISPR Therapeutics appointed Bill Lundberg to Chief Scientific Officer to lead the company’s development programs and to spearhead the creation of its R&D operations in Cambridge, Massachusetts. The biopharmaceutical company was founded in Basel, Switzerland, by Emanuelle Charpentier, one of the pioneer scientists in the CRISPR field. The company is focused on translating CRISPR-Cas9 gene-editing […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Apr 2015

The Strategic Focus of Roche-Genentech on Personal Genetic data

Personal Genetic data plays more and more a critical role in drug development. Major Pharma company Roche and its Biotech subsidiary Genentech are iconic in this trend. They have always been the first ones to catch up the wave and get profit from it. Today, Genentech believes and focus on genome sequencing to continue bringing breakthrough […]

April 3, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 2 Apr 2015

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

Anergis announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. Anergis’ approach uses synthetic, pharmaceutical-grade Contiguous Overlapping Peptide (“COP”), peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they […]

April 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 20 Mar 2015

Let’s Focus on Calypso Biotech, a New Promising Startup that Concentrates on Niche Gastro-intestinal Diseases

Last week, I was in Bio Spring Europe and I met Alain Vicari, Calypso Biotech’s CEO: What is Calypso Biotech? Calypso Biotech discovers and develops antibody therapies for indications in gastro-intestinal diseases. The company tackles on niche diseases, with therapeutic antibodies against difficult targets. Calypso was founded in Geneva, in 2013, as a spin-off of […]

March 20, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 19 Mar 2015

Syngenta corn trait expansion further continues thanks the Vietnamese approval

A few days ago, Syngenta announced that the Vietnamese Ministry of Natural Resources and Environment has approved its Bt11 x GA21 double stack corn seed for commercial cultivation in the country. Syngenta, one of the world’s leading companies in the field of Green Biotechnology, have more than 28,000 employees in over 90 countries. The company […]

March 19, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 18 Mar 2015

Novartis’ Jakavi receives European Commission approval

Novartis received the approval from the European Commission for Jakavi (ruxolitinib) for the treatment of adult patients with Polycythemia Vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. PV is a rare and incurable blood cancer associated with an overproduction […]

March 18, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us